Table 4 Immunotherapy in soft tissue sarcomas

Mackall et al., 2016 [88]

Synovial sarcoma

I/II, recruiting

NY-ESO-1c259 SPEAR T-cells

Cohort 1 and 2: FL 30 mg/m²/day, day 1–4; CTX 1800 mg/m²/day day 1–2

Cohort 3: CTX 1800 mg/m²/day day 1–2

Cohort 4: FL 30 mg/m²/day, day 1–3; CTX 600 mg/m²/day; day 1–3

Cohort 1: 15

Cohort 2: 2

Cohort 3: 2

Cohort 4: 0

Cohort 1: 50

Cohort 2: NA

Cohort 3: NA

Cohort 4: NA

Italiano et al., 2016 [90]

LMS (Arm A), UPS (Arm B), GIST (Arm C), OS (Arm D), other sarcomas (Arm E)

II, recruiting in arm B and D

Pembrolizumab 200 mg i.v. 3-weekly; CTX 50 mg BID 1week on, 1 week off

Arm A: 15

Arm B: 0

Arm C: 10

Arm D: 0

Arm E: 16

No objective responses

Burgess et al., 2016 [89]

All-type STS (arm A) and BS (arm B)

II, completed

Pembrolizumab, 200mg i.v., 3-weekly

Arm A: 40

Arm B: 40

Arm A: 17.5

(UPS, LPS, SS)

Arm B: 5 (OS, CS)

Paoluzzi et al., 2016 [91]

All-type STS and BS

Retrospective

Arm A: nivolumab 3 mg/kg i.v., 2-weekly

Arm B: nivolumab 3 mg/kg i.v., 2-weekly + pazopanib 800 mg/day

Arm A: 10

Arm B: 18

Arm A: 10 (CS)

Arm B: 11 (ES, OS)

George et al., 2016 [90]

Leiomyosarcoma

II

Nivolumab 3 mg/kg i.v., 2-weekly

12

No objective responses